The 4-Month Isoniazid, Rifapentine, Moxifloxacin, and Pyrazinamide Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis: A Word of Caution
American Journal of Respiratory and Critical Care Medicine | June 13, 2025 | Volume: 211 | Issue: 8 | Pages: 1525-1525
10.1164/rccm.202501-0222le